Photobiomodulation: Promising future for treating drusenoid pigment epithelial detachments in dry AMD

The outcome measures were the best-corrected visual acuity (BCVA), microperimetry- scotopic testing, drusen volume (DV), central drusen thickness, and the quality of life score at baseline and month 6 visits. (Image Credit: Adobe Stock/Nejron Photo) Photobiomodulation is an emerging treatment for dry age-related macular degeneration (AMD). Investigators who tested it in a pilot study reported that it seems to be a valid therapeutic option to treat large soft drusen and drusenoid pigment epithelial detachments (PED) in dry AMD and may potentially slow the natural disease course.1 https://www.modernretina.com/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fmodernretina%2Fadd7b2297ceb62299a478eb4321009f02754ed38-1200x803.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 https://cdn.sanity.io/images/0vv8moc6/modernretina/add7b2297ceb62299a478eb4321009f02754ed38-1200x803.jpg?fit=crop&auto=format